ZYME (Zymeworks Corp) חוב לטווח ארוך
Strategic risks for Zymeworks Inc. (ZYME) are linked to an inflated rate for a single drug and research costs, with the indicator standing at 0.28. Zymeworks Inc. (ZYME) is developing multispecific antibodies, relying on the support of major partners to advance zanidatamab. This price chart reflects the asset's dynamics, whose resilience is based on technology licensing and the diversification of oncology projects to secure stable royalties.
פילוחי מדדים פיננסיים ומדדי שוק עבור Zymeworks Corp (ZYME)
Long-term debt aggregates loan and bond obligations with maturities exceeding one year, allowing for an assessment of the debt load and the cost of borrowed capital. By analyzing the value of the firm's long-term borrowings, an investor determines the financial stability of Zymeworks Inc. (ZYME), which is bolstered by the cyclical independence of cancer immunotherapy and stable demand for treatment regardless of market turmoil.